Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and
Tempest partnered with a Chinese research group to test a new medicine called TPST-4003 on about 10 patients starting late 2026. This shows the company is moving forward with their research, though it's still very early stages.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.